Werewolf Therapeutics released a positive SITC update for WTX-124 showing IL-2 INDUKINE can hide in plain site, H.C. Wainwright analyst Andres Maldonado tells investors in a research note. It’s clear that WTX-124 is exhibiting dose-proportional PK which thus far has yielded low levels of active IL-2, which is responsible for the improvement of the safety profile, the firm says. No change was made to the firm’s Buy rating or $15 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HOWL:
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to present clinical, preclinical data at SITC meeting
- Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
- Werewolf Therapeutics to Participate in Upcoming Investor Conferences
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue